Categories
GeekWire

Positive results for ‘tumor-agnostic’ cancer drug

Ted Laetsch
UT Southwestern Medical Center’s Ted Laetsch is the lead author of a study focusing on how a drug called larotrectinib can be used to treat pediatric cancer patients. (UT Southwestern Photo)

Two clinical studies have provided evidence suggesting that an experimental precision-medicine drug called larotrectinib can fight soft-tissue tumors regardless of the patient’s age or the type of tumor.

Seattle Children’s Hospital participated in both studies.

Get the full story on GeekWire.

By Alan Boyle

Mastermind of Cosmic Log, contributing editor at GeekWire, author of "The Case for Pluto: How a Little Planet Made a Big Difference," president of the Council for the Advancement of Science Writing. Check out "About Alan Boyle" for more fun facts.

Leave a Reply